The filing delivers financing flexibility, not fresh cash. Core Scientific entered a new credit agreement dated August 25, 2026, but the filing does not disclose that any revolving loans were drawn at closing. The facility consists of a $100 million revolver and a $500 million letter-of-credit facility, so the headline $600 million commitment materially overstates immediately usable cash liquidity. 〔0〕
| Facility | Commitment | Pricing / fee | Maturity |
|---|---|---|---|
| Revolving facility | $100 million | Term SOFR + 1.75%; 0.25% unused fee | 3 years, with a one-year extension option |
| Letter-of-credit facility | $500 million | Participation fee tied to revolver pricing; 0.125% fronting fee | Same maturity framework |
| Liquidity covenant | Minimum $150 million | Includes cash plus unused revolver capacity | Tested quarterly |
The main improvement is tenor and structure. The agreement gives the company a three-year bank facility, extendable to four years at its discretion, replacing a short-term funding mindset with a more durable liquidity backstop. That is useful for working capital and project-related credit support, but the filing does not provide evidence of lower debt, refinancing savings, or cash proceeds.
Lender protections are meaningful, limiting the upside signal. Borrowing is conditioned on at least $150 million of liquidity and a market capitalization of at least $3 billion; the company can cure a liquidity shortfall with equity issuance, but only a limited number of times. The collateral package covers broad personal property and intellectual property, while project assets can remain outside the collateral pool where project documents restrict pledges. 〔1〕
Net read: a modestly better financing setup, but not a clear earnings-style beat. The market likely expected Core Scientific to maintain financing access as its data-center buildout expands; the new details are the longer maturity, the $500 million LC capacity, and the relatively small $100 million cash revolver. With no funded borrowing, no stated refinancing benefit, and tighter eligibility conditions, this lands as mixed rather than unequivocally positive.
Read the original 8-K on SEC EDGAR ↗